Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
78 results about "Potassium channel opener" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A potassium channel opener is a type of drug which facilitates ion transmission through potassium channels.
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
InactiveUS20060051418A1Enhanced drug releaseReduces food uptakeBiocideOrganic active ingredientsPotassium channel openerPotassium
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
Owner:ESSENTIALIS INC
Organ arrest, protection, preservation and recovery
InactiveUS20050202394A1Reduced uptakeBiocideOrganic active ingredientsPotassium channel openerPotassium
The present invention relates to a composition for controlling viability of a tissue including a potassium channel opener or adenosine receptor agonist, a compound for inducing local anaesthesia and a compound for reducing the uptake of water by a cell in the tissue. The present invention also realtes to the use of the composition accordng to the invention for controlling viability of a tissue.
Owner:HIBERNATION THERAPEUTICS A KF
Pharmaceutical compositions
Owner:OMEROS CORP
Surgical irrigation solution and method for inhibition of pain and inflammation
A method and solution for perioperatively inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including oral / dental procedures. The solution preferably includes multiple pain and inflammation inhibitory at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain and inflammation includes a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokinin1 antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykinin1 antagonist, a bradykinin2 antagonist and a mu -opioid agonist.
Owner:OMEROS CORP
Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
InactiveUS20100256145A1Quick effectGood effectBiocideNervous disorderKCNQ Potassium ChannelsPotassium channel opener
The invention relates, inter alia, to a method for reducing symptoms of, or for treating, one or more disorders or conditions wherein the dopaminergic system is disrupted, the method comprising administering to a host in need thereof an effective amount of a compound that is able to increase the ion flow through KCNQ potassium channels.
Owner:H LUNDBECK AS
Novel benzopyran derivatives as potassium channel openers
The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.
Owner:JANSSEN PHARMA NV
Salts of potassium atp channel openers and uses thereof
ActiveUS20070191351A1Enhanced drug releaseNervous disorderAmino preparation from aminesDiseasePotassium
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Owner:ESSENTIALIS INC
Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
Owner:ABBOTT LAB INC
Salts of potassium atp channel openers and uses thereof
InactiveUS20090062264A1Inhibit and prevent progressionReducing insulin dosingMetabolism disorderDigestive systemDiseasePotassium channel opener
Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Owner:ESSENTIALIS INC
Transplants
InactiveUS20100119554A1Easy to storeImprove protectionBiocideBacterial antigen ingredientsPotassium channel openerAgonist
The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent.
Owner:HIBERNATION THERAPEUTICS A KF
A method for organ arrest, protection and preservation and reducing tissue injury
InactiveCN105579045ANervous disorderHydroxy compound active ingredientsDiseasePotassium channel opener
The invention relates to compositions and methods for Inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention, and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) citrate.
Owner:低温药理KF有限公司
Pharmaceutical formulations of potassium atp channel openers and uses thereof
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
Owner:ESSENTIALIS INC
Organ preconditioning, arrest, protection, preservation and recovery
InactiveUS20090325878A1Heavy metal active ingredientsBiocidePotassium channel openerRest membrane potential
Owner:HIBERNATION THERAPEUTICS A KF
Organ arrest, protection, preservation and recovery
InactiveUS20080293034A1Reduced uptakeOrganic active ingredientsElectrotherapyPotassium channel openerPotassium
Owner:HIBERNATION THERAPEUTICS A KF
Organ protection, preservation and recovery
InactiveUS20100256083A1Avoid damageReduce injuriesBiocideNervous disorderPotassium channel openerAgonist
This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and / or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ.
Owner:HIBERNATION THERAPEUTICS A KF
Potassium channel openers
Owner:ABBVIE INC
Heteronuclear compound with dicyandiamide connection and its medicinal use
A heterocyclic compound with ethyl guanidine connection and its medicinal use are disclosed. The compound contains optical isomer or diastereomeric mixture, their medicinal salt, group and potassium channel developer and calcium spiking agent. It can be used to treat and prevent cardiac lassitude and cardiovascular diseases.
Owner:李伟章
Potassium channel opener
A potassium channel opener including a compound (e.g., pimaric acid) represented by the formula [I]: wherein R1, R2, R3, R4, R5, R6 and R7 are each independently hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde, or nitrile; or R4 and R5 may be bonded to each other to form a ring; or R6 and R7 may be bonded to each other to form a ring; and all of three bonds represented by are single bonds, or one of the three bonds is double bond and the other bonds are single bonds, or a physiologically acceptable salt thereof as an effective ingredient.
Owner:MITSUBISHI TANABE PHARMA CORP
Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
Owner:ABBOTT LAB INC
Transplants
InactiveUS20130143833A1Increase storage spaceReduce vasospasmBiocideSurgical drugsPotassium channel openerAgonist
The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and / or an adenosine receptor agonist; and (ii) an antiarrhythmic agent.
Owner:HIBERNATION THERAPEUTICS A KF
Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
InactiveCN1694717AIncrease incidenceReduce total drug doseAntipyreticAnalgesicsPotassium channel openerHistamine antagonists
A method and solution for perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation processes at wounds from general surgical procedures including oral / dental procedures. The solution preferably includes at least one anti-tumor cell adhesion agent and multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit tumor cell adhesion, pain and inflammation includes at least one anti-tumor cell adhesion agent, a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokininl antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykininl antagonist, a bradykinin2 antagonist and a mu -opioid agonist.
Owner:OMEROS CORP
Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3- dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Owner:XENON PHARMACEUTICALS INC
A method for treating haemorrhage, shock and brain injury
InactiveCN105705151ANervous disorderHydroxy compound active ingredientsInjury brainLocal anaesthetic
Owner:低温药理KF有限公司
Improved tissue maintenance
InactiveCN101500409APromote generationSobriety recoveryOrganic active ingredientsSurgical drugsLocal anaestheticPotassium channel opener
The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener / agonist and / or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.
Owner:HIBERNATION THERAPEUTICS LTD
Novel compositions of potassium channel openers and protein kinase C inhibitors and use thereof
Novel compositions comprising a potassium channel opener, such as minoxidil, and a protein kinase C inhibitor, such as procyanidin B2 are presented, as are kits containing a first composition comprising a potassium channel opener and a second composition comprising a protein kinase C inhibitor. Also presented are methods for using the novel compositions for treating and preventing hair loss in a region of a patient.
Owner:PHARMACIA AB
Benzopyran derivatives as potassium channel openers
Owner:JANSSEN PHARMA NV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com